Why the study?
Visceral adiposity is linked to cardiometabolic disorders, but evidence on the extent of visceral fat loss required to significantly improve cardiometabolic markers remains limited.
Does visceral fat area loss improve cardiometabolic markers in adults with overweight and obesity?
Does visceral fat area loss improve cardiometabolic markers in adults with overweight and obesity?
A visceral fat area loss of ≥ 5% following a dietary intervention is associated with significant improvements in cardiometabolic markers including HDL-C, triglycerides, and HbA1c.
Background: Visceral adiposity is closely linked with cardiometabolic disorders, but evidence on the extent of visceral fat loss required for significant improvement in cardiometabolic markers remains limited. This study aims to investigate the association between visceral fat area (VFA) reductions and improvements in cardiometabolic markers following a 3-month dietary intervention. Methods: A total of 175 adults with overweight and obesity were involved in this non-randomized controlled trial. Data on sociodemographic, anthropometric, body composition and biochemistry were collected at baseline and after 3 months of intervention. The multiple logistic regression analysis was conducted to determine the association between VFA loss (no loss, < 5% loss, and ≥ 5% loss) and improvement in cardiometabolic markers. For each cardiometabolic marker, an improvement surpassing the minimum threshold of the third tertile was classified as a good improvement. Results: Compared to those with no VFA loss, participants with VFA loss of ≥ 5% were significantly associated with a higher improvement in waist circumference (OR 2.97, 95% CI 1.16-7.64), high-density lipoprotein cholesterol (HDL-C) (OR 4.19, 95% CI 1.58-11.14), triglycerides (OR 3.01, 95% CI 1.14-7.92), and glycated hemoglobin (HbA1C) (OR 2.95, 95% CI 1.12-7.79). Other than that, those with < 5% VFA loss were 3.6 times more likely to have a higher improvement in HDL-C compared to those with no VFA loss (OR 4.08, 95% CI 1.36-12.22). Conclusion: This study found that the magnitude of VFA loss is an independent determinant of improvements in cardiometabolic markers and should be set as a clear target when designing obesity prevention programs.
No takes yet. Share an insight, caveat, or question.
Abdullah et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: